Cracking the Blood–Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological Therapies
Pharmaceutics · 06.09.2025 · 17 (9) · 1169
DOI: 10.3390/pharmaceutics17091169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.09.2025. Verfasst von Lucio Nájera-Maldonado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada (CICATA) Unidad Morelos del Instituto Politécnico Nacional (IPN), Boulevard de la T…. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Politécnico Nacional, Convocatoria de Ciencia Básica y de Frontera 2025 of SECIHTI, Secretaría de Investigación y Posgrado.
Abstract (Originalsprache)
This review provides a mechanistic framework to strategically design nanoparticles capable of efficiently crossing the blood–brain barrier (BBB), a critical limitation in neurological treatments. We systematically analyze nanoparticle–BBB transport mechanisms, including receptor-mediated transcytosis, adsorptive-mediated transcytosis, and transient barrier modulation. Essential nanoparticle parameters (size, shape, stiffness, surface charge, and biofunctionalization) are evaluated for their role in enhancing brain targeting. For instance, receptor-targeted nanoparticles can significantly enhance brain uptake, achieving levels of up to 17.2% injected dose per gram (ID/g) in preclinical glioma models. Additionally, validated preclinical models (human-derived in vitro systems, rodents, and non-human primates) and advanced imaging techniques crucial for assessing nanoparticle performance are discussed. Distinct from prior BBB nanocarrier reviews that primarily catalogue mechanisms, this work (i) derives quantitative ‘design windows’ (size 10–100 nm, aspect ratio ~2–5, near-neutral ζ) linked to transcytosis efficiency, (ii) cross-walks human-relevant in vitro/in vivo models (including TEER thresholds and NHP evidence) into a translational decision guide, and (iii) integrates regulatory/toxicology readiness (ISO 10993-4, FDA/EMA, ICH) into practical checklists. We also curate recent (2020–2025) %ID/g brain-uptake data across lipidic, polymeric, protein, inorganic, and hybrid vectors to provide actionable, evidence-based rules for BBB design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada (CICATA) Unidad Morelos del Instituto Politécnico Nacional (IPN), Boulevard de la Tecnología No. 1036, Xochitepec 62790, Mexico.
- Departamento de Ciencias de la Computación, Universidad Católica de Murcia (UCAM), Av. de los Jerónimos, 135, 30107 Murcia, Spain.
ORCID-Profile: Mariana Parra-González, Esperanza Peralta-Cuevas, Igor Garcia-Atutxa, Francisca Villanueva-Flores
Förderung
- Instituto Politécnico Nacional
- Convocatoria de Ciencia Básica y de Frontera 2025 of SECIHTI
- Secretaría de Investigación y Posgrado
- SECIHTI
Zitieren
APA
Nájera-Maldonado, L., Parra-González, M., Peralta-Cuevas, E., Gutierrez-Onofre, A. J., Garcia-Atutxa, I., & Villanueva-Flores, F. (2025). Cracking the Blood–Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological Therapies. Pharmaceutics, 17(9), 1169. https://doi.org/10.3390/pharmaceutics17091169
Vancouver
Nájera-Maldonado L, Parra-González M, Peralta-Cuevas E, Gutierrez-Onofre AJ, Garcia-Atutxa I, Villanueva-Flores F. Cracking the Blood–Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological Therapies. Pharmaceutics. 2025;17(9):1169. doi:10.3390/pharmaceutics17091169
BibTeX
@article{NjeraMaldonado2025,
author = {Nájera-Maldonado, Lucio and Parra-González, Mariana and Peralta-Cuevas, Esperanza and Gutierrez-Onofre, Ashley J and Garcia-Atutxa, Igor and Villanueva-Flores, Francisca},
title = {Cracking the Blood–Brain Barrier Code: Rational Nanomaterial Design for Next-Generation Neurological Therapies},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1169},
doi = {10.3390/pharmaceutics17091169}
}
EUVIMED